Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06744712 · ClinicalTrials.gov registry record · NA
Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients
A NA study, sponsored by Wake Forest University Health Sciences.
- Not yet
- Registry status
- NA
- Development phase
- 130
- Enrollment target
NCT06744712 is a NA study that has not yet begun recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 130 participants.
The verdict
NCT06744712, a NA study, has not yet begun recruiting, sponsored by Wake Forest University Health Sciences.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
Study Summary
Pharmacogenomic (PGx) testing involves analyzing variants of genes associated with drug metabolism, transport and medication targets. PGx testing uses an individual's genetic factors, such as single nucleotide polymorphisms (SNPs), to personalize therapy or dose a selection of medications. PGx testing has traditionally been used to test single genes, but there are now platforms allowing a panel of genes to be tested at once. To date there has not been a comprehensive screening of pediatric oncology patients to determine the prevalence of genetic variants that may affect anticancer therapy and supportive care medications. This study would allow us to summarize the frequency of clinically relevant gene-drug interactions and actionable genetic polymorphisms in pediatric oncology patients.
Interventions
- OTHER Pharmacogenomic Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2026-08 |
| Est. Completion | 2028-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06744712
The ClinicalTrials.gov registry entry for NCT06744712 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pharmacogenomic Testing is the first listed.
NCT06744712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06744712 about?
NCT06744712 is a clinical study titled "Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients". Pharmacogenomic (PGx) testing involves analyzing variants of genes associated with drug metabolism, transport and medication targets. PGx testing uses an individual's genetic factors, such as single nucleotide polymorphisms (SNPs), to personalize therapy or dose a selection of medications. PGx testi...
What is the current status of trial NCT06744712?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2026-08. Estimated completion is 2028-07.
What interventions are being tested in trial NCT06744712?
The interventions under investigation include: Pharmacogenomic Testing (OTHER).
Who is sponsoring clinical trial NCT06744712?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.